S&P 500
5.469,30 +21,43 (+0,39%) Nasdaq
17.717,65 +220,84 (+1,26%) NIKKEI 225
39.676,80 +503,65 (+1,29%) Dólar/Euro
1,0714 -0,0002 (-0,02%) Petróleo Brent
85,36 +0,35 (+0,41%) Bitcoin EUR
57.658,02 +471,55 (+0,82%)
FOXO Technologies Inc. (FOXO)
Después del cierre:
FOXO Technologies Inc.
729 North Washington Avenue
Suite 600
Minneapolis, MN 55401
United States
612 562 9447
https://foxotechnologies.com
Sector(es): Healthcare
Sector: Health Information Services
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Mark Brian White | Interim CEO & Director | N/A | N/A | 1960 |
| Mr. Martin Christopher Ward FCA | Interim Chief Financial Officer | N/A | N/A | 1957 |
| Mr. Jim Grauel Jr. | Chief Distribution Officer | N/A | N/A | N/A |
| Ms. Susan Neo | Chief Security Officer | N/A | N/A | N/A |
Descripción
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.
Gobierno corporativo
El ISS Governance QualityScore de FOXO Technologies Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
